Kinase drug discovery 20 years after imatinib: progress and future directions

The challenge of identifying which stage III melanoma patients need adjuvant treatment and with what

(2020) P. Nathan   ANNALS OF ONCOLOGY

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

(2020) Benjamin J. Solomon et al.   Journal of Thoracic Oncology

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

(2020) Robert H Jones et al.   LANCET ONCOLOGY

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study

(2020) T. Mok et al.   ANNALS OF ONCOLOGY

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

(2020) Robin M. J. M. van Geel et al.   BRITISH JOURNAL OF CANCER

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

(2020) Lillian M Smyth et al.   CLINICAL CANCER RESEARCH

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

(2020) Vladimir Sapon-Cousineau et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis

(2020) Michael D. Wiese et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations

(2020) Philippe Jamme et al.   Journal of Thoracic Oncology

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

(2020) Seth A. Wander et al.   Cancer Discovery

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma

(2020) Nityam Rathi et al.   Cancer Management and Research

Clinical Challenges of Immune Checkpoint Inhibitors

(2020) Maria de Miguel et al.   CANCER CELL

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

(2020) J.J. Lin et al.   ANNALS OF ONCOLOGY

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

(2020) John Jiang et al.   BMC CANCER

Structural basis for the action of the drug trametinib at KSR-bound MEK

(2020) Zaigham M. Khan et al.   NATURE

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

(2020) Reinhard Dummer et al.   NATURE MEDICINE

Kinase inhibition in autoimmunity and inflammation

(2020) Ali A. Zarrin et al.   NATURE REVIEWS DRUG DISCOVERY

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

(2020) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

(2020) Yi-Long Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors

(2020) Emiliano Cocco et al.   Cancer Discovery

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance

(2020) Claudio D’Amore et al.   CELLULAR ONCOLOGY

Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges

(2020) Shenxin Zeng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

TAM kinase inhibition and immune checkpoint blockade– a winning combination in cancer treatment?

(2020) Pavlos Msaouel et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

(2020) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence

(2020) Kamal Pandey et al.   Cancers

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

(2019) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

(2019) Anniina T. Virtanen et al.   BIODRUGS

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors

(2019) Jing-Wen Li et al.   CANCER BIOLOGY & THERAPY

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

(2019) Jorge E. Cortes et al.   CURRENT MEDICAL RESEARCH AND OPINION

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single and dual targeting of mutant EGFR with an allosteric inhibitor

(2019) Ciric To et al.   Cancer Discovery

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation

(2019) George M Burslem et al.   CANCER RESEARCH

Small-Molecule CSF1R Inhibitors as Anticancer Agents

(2019) Xiaoyun Lu et al.   CURRENT MEDICINAL CHEMISTRY

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

(2019) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure-guided fragment-based drug discovery at the synchrotron: screening binding sites and correlations with hotspot mapping

(2019) Sherine E. Thomas et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES

Crizotinib-induced immunogenic cell death in non-small cell lung cancer

(2019) Peng Liu et al.   Nature Communications

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader

(2019) Hannah Tovell et al.   ACS Chemical Biology

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer

(2019) Alessandro Leonetti et al.   BRITISH JOURNAL OF CANCER

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

(2019) Christopher A. Eide et al.   CANCER CELL

A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

(2019) Yuuri Hashimoto et al.   CLINICAL CANCER RESEARCH

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

(2019) Vanita Noronha et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances of Wnt signalling pathway in dental development and potential clinical application

(2019) Xi Lu et al.   Organogenesis

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

(2019) Gonzalo Recondo et al.   CLINICAL CANCER RESEARCH

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

(2019) Yukio Hosomi et al.   JOURNAL OF CLINICAL ONCOLOGY

The great escape: tumour cell plasticity in resistance to targeted therapy

(2019) Soufiane Boumahdi et al.   NATURE REVIEWS DRUG DISCOVERY

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Salt-inducible kinase 1 regulates bone anabolism via the CRTC1–CREB–Id1 axis

(2019) Min Kyung Kim et al.   Cell Death & Disease

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

(2019) Carlotta Costa et al.   Cancer Discovery

The Molecular Genetics of Gordon Syndrome

(2019) Holly Mabillard et al.   Genes

The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells

(2019) Giovanni Di Maira et al.   Oncogenesis

New Promise and Opportunities for Allosteric Kinase Inhibitors

(2019) Xiaoyun Lu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

(2019) James C.H. Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

(2019) Timothy P. Hughes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective RET kinase inhibition for patients with RET-altered cancers

(2018) V Subbiah et al.   ANNALS OF ONCOLOGY

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells

(2018) Ahrum Min et al.   CANCER LETTERS

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

(2018) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

(2018) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

(2018) David R. Spigel et al.   Journal of Thoracic Oncology

Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection

(2018) Christopher Abbosh et al.   Nature Reviews Clinical Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

LRRK2 kinase in Parkinson's disease

(2018) Dario R. Alessi et al.   SCIENCE

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

(2018) Satoshi Yoda et al.   Cancer Discovery

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

(2018) Vivek Subbiah et al.   Cancer Discovery

Ras-Mediated Activation of the Raf Family Kinases

(2018) Elizabeth M. Terrell et al.   Cold Spring Harbor Perspectives in Medicine

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

(2018) Moshe Talpaz et al.   Journal of Hematology & Oncology

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer

(2018) D. Ross Camidge et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   RHEUMATOLOGY

LRRK2 activation in idiopathic Parkinson’s disease

(2018) Roberto Di Maio et al.   Science Translational Medicine

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

(2018) Alexander Drilon et al.   Cancer Discovery

Neurodegeneration in SCA14 is associated with increased PKCγ kinase activity, mislocalization and aggregation

(2018) Maggie M. K. Wong et al.   Acta Neuropathologica Communications

The clinical role of the TME in solid cancer

(2018) Nicolas A. Giraldo et al.   BRITISH JOURNAL OF CANCER

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

(2018) Ken Suzawa et al.   CLINICAL CANCER RESEARCH

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

(2018) Benjamin J Solomon et al.   LANCET ONCOLOGY

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases

(2018) Jessica J. Lin et al.   Journal of Thoracic Oncology

Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy

(2017) Nicole Glodde et al.   IMMUNITY

Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials

(2017) Koung Jin Suh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

(2017) Oliver Gautschi et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

(2017) David Planchard et al.   LANCET ONCOLOGY

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

(2017) Hatim Husain et al.   MOLECULAR CANCER THERAPEUTICS

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

(2017) Andrew A. Wylie et al.   NATURE

Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels

(2017) Timothy P Heffron   NEURO-ONCOLOGY

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin

(2017) Nisma Mujahid et al.   Cell Reports

Promotion of natural tooth repair by small molecule GSK3 antagonists

(2017) Vitor C. M. Neves et al.   Scientific Reports

Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of macrophages

(2016) Nicola J. Darling et al.   BIOCHEMICAL JOURNAL

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

(2016) G. Yang et al.   BLOOD

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

(2016) Marion Rudolph et al.   BMC CANCER

High-throughput Phenotyping of Lung Cancer Somatic Mutations

(2016) Alice H. Berger et al.   CANCER CELL

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Olmutinib: First Global Approval

(2016) Esther S. Kim   DRUGS

Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)

(2016) W. Michael Seganish   EXPERT OPINION ON THERAPEUTIC PATENTS

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

(2016) Lucio Crinò et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

(2016) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Degradation of Akt using protein-catalyzed capture agents

(2016) Ryan K. Henning et al.   JOURNAL OF PEPTIDE SCIENCE

Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

(2016) Scott N Gettinger et al.   LANCET ONCOLOGY

Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

(2016) Alice T Shaw et al.   LANCET ONCOLOGY

Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

(2016) David Planchard et al.   LANCET ONCOLOGY

Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

(2016) Joshua D Campbell et al.   NATURE GENETICS

Coming of age: ten years of next-generation sequencing technologies

(2016) Sara Goodwin et al.   NATURE REVIEWS GENETICS

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

(2016) Susan Ashton et al.   Science Translational Medicine

SIKs control osteocyte responses to parathyroid hormone

(2016) Marc N. Wein et al.   Nature Communications

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members

(2015) Nazma Malik et al.   BIOCHEMICAL JOURNAL

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

(2015) Sheng-Bin Peng et al.   CANCER CELL

Mechanisms of lapatinib resistance in HER2-driven breast cancer

(2015) Valentina D’Amato et al.   CANCER TREATMENT REVIEWS

Axitinib: A Review in Advanced Renal Cell Carcinoma

(2015) Gillian M. Keating   DRUGS

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

(2015) Qingbei Zeng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comprehensive characterization of the Published Kinase Inhibitor Set

(2015) Jonathan M Elkins et al.   NATURE BIOTECHNOLOGY

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

(2015) S.-H. I. Ou et al.   ONCOLOGIST

Prediction of Cancer Drug Resistance and Implications for Personalized Medicine

(2015) Manfred Volm et al.   Frontiers in Oncology

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

(2014) H. A. Yu et al.   ANNALS OF ONCOLOGY

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma

(2014) I. W. Flinn et al.   BLOOD

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

(2014) Pernelle Lavaud et al.   BMC Medicine

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

(2014) Ted W. Johnson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

(2014) Dejan Juric et al.   NATURE

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology

(2014) Pietro Ciceri et al.   Nature Chemical Biology

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

(2014) E. C. de Bruin et al.   Cancer Discovery

Developing Irreversible Inhibitors of the Protein Kinase Cysteinome

(2013) Qingsong Liu et al.   CHEMISTRY & BIOLOGY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial

(2012) S. Oizumi et al.   ONCOLOGIST

Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages

(2012) K. Clark et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

PI3K-PKB/Akt Pathway

(2012) B. A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

Wnt Signaling and Injury Repair

(2012) J. L. Whyte et al.   Cold Spring Harbor Perspectives in Biology

Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or I B  Deficiency

(2011) C. Picard et al.   CLINICAL MICROBIOLOGY REVIEWS

Structural biology in fragment-based drug design

(2010) Christopher W Murray et al.   CURRENT OPINION IN STRUCTURAL BIOLOGY

VHL and HIF signalling in renal cell carcinogenesis

(2010) Marcella M Baldewijns et al.   JOURNAL OF PATHOLOGY

Clinical Features and Outcome of Patients With IRAK-4 and MyD88 Deficiency

(2010) Capucine Picard et al.   MEDICINE

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

"Go upstream, young man": lessons learned from the p38 saga

(2009) D Hammaker et al.   ANNALS OF THE RHEUMATIC DISEASES

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

(2009) Kim-Son H. Nguyen et al.   Clinical Lung Cancer

Targeting protein kinases for the development of anti-inflammatory drugs

(2009) Philip Cohen   CURRENT OPINION IN CELL BIOLOGY

Nilotinib: A second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

(2009) Massimo Breccia et al.   LEUKEMIA RESEARCH

Pazopanib

(2009) Ronald M. Bukowski et al.   NATURE REVIEWS DRUG DISCOVERY

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

Inhibitors of ABL and the ABL-T315I Mutation

(2008) Glenn Noronha et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA